| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1368781 | Bioorganic & Medicinal Chemistry Letters | 2016 | 6 Pages |
As a follow-up to the GPR40 agonist AMG 837, which was evaluated in clinical trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 (13k). AM-3189 is representative of a new class of compounds with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837.
Graphical abstractAs a follow-up to the GPR40 agonist AMG 837, which was evaluated in clinical trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 (13k). AM-3189 is representative of a new class of compounds with minimal CNS penetration, superior pharmacokinetic properties and comparable in vivo efficacy.Figure optionsDownload full-size imageDownload as PowerPoint slide
